99mTc-TRODAT-1 imaging of multiple system atrophy

Journal of Nuclear Medicine

Volumn 45, Issue 1, 2004, Pages 49-55

  Lu, Chin Song ^a   Weng, Yi Hsin ^a   Chen, Min Chi ^a   Chen, Rou Shayn ^a   Tzen, Kai Yuan ^a   Wey, Shiaw Pyng ^b   Ting, Gann ^b   Chang, Hsiu Chen ^a   Yen, Tzu Chen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

99mTc TRODAT 1 brain SPECT; Dopamine transporter; Multiple system atrophy; Parkinson's disease

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; CARRIER PROTEIN; DIAGNOSTIC AGENT; DOPAMINE TRANSPORTER; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M TRODAT 1; TECHNETIUM TC 99M TRODAT-1; TROPANE DERIVATIVE;

ANALYSIS OF VARIANCE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORPUS STRIATUM; DIFFERENTIAL DIAGNOSIS; FEMALE; MALE; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NERVE TISSUE PROTEINS; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TROPANES;

EID: 1842556157     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Quinn NP. Multiple system atrophy. In Marsden CD, Fahn S, eds. Movement Disorders 3. London, U.K.: Butterworth-Heinemann; 1994:262-281.
2. Wenning GK, Tison F, Ben Shlomo Y, et al. Multiple system atrophy: a review of 203 pathological proven cases. Mov Disord. 1997;12:133-147.
3. Wenning GK, Ben-Shlomo Y, Hughes A, Deniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;68:434-440.
4. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002;125:1070-1083.
5. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163:94-98.
6. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1995;58:160-166.
7. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci. 1989;94:79-100.
8. Tu P-H, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann Neurol. 1998;44:415-422.
9. Dickson DW, Liu W-K, Hardy J, et al. Widespread alteration of alpha-synuclein in multiple system atrophy. Am J Pathol. 1999;155:1241-1251.
10. Kawamoto Y, Akiguchi I, Nakamura S, Budka H. Accumulation of 14-3-3 proteins in glial cytoplasmic inclusions in multiple system atrophy. Ann Neurol. 2002;52:722-731.
11. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci. 1991;18:275-278.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
13. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990;28:547-555.
14. Gilman S, Koeppe RA, Junck L, et al. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. Ann Neurol. 1999;45:769-777.
15. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995;38:589-598.
16. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46:231-237.
17. 123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000;15:1158-1167.
18. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal β-CIT SPECT study. Mov Disord. 2002;17:45-53.
19. 99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 1997;24:372-380.
20. 99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med. 1999;41:584-589.
21. 99mTc-TRODAT-1. J Nucl Med. 2001;42:408-413.
22. Yen TC, Lu CS, Tzen KY, et al. Decreased dopamine transporter binding in Machado-Joseph disease. J Nucl Med. 2000;41:994-998.
23. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol. 1992;32:S125-S127.
24. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
25. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA. 1993;90:11965-11969.
26. Jones SR, Gainetdinov RR, Hu XT, et al. Loss of autoreceptor function in mice lacking the dopamine transporter. Nat Neurosci. 1999;2:649-655.
27. 123I]Beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord. 2001;16:1023-1032.
28. 99mTc-TRODAT-1 imaging. J Nucl Med. 2001;42:1303-1308.
29. Rinne JO, Burn DJ, Mathias CJ, Quinn NP, Marsden CD, Brooks DJ. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol. 1995;37:568-573.
30. Wenning GK, Tison F, Elliott L, Quinn NP, Daniel SE. Olivopontocerebellar pathology in multiple system atrophy. Mov Disord. 1996;11:157-162.
31. Fearnley JM, Lees AJ. Striatonigral degeneration: a clinicopathological study. Brain. 1990;113:1823-1842.
32. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:133-140.